# US 6,730,663 B2 · Targeting gene expression to living tissue using jet injection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,663 B2
- Document ID: US6730663B2
- Status: Granted
- Kind: B2
- Application number: 10/037,616
- Filed: 2002-01-02
- Published: 2002-09-05
- Granted: 2004-05-04
- Earliest claimed: 1992-05-21
- Assignees: The United States of America as represented by the Department of Health and Human Services
- Inventors: Priscilla Anne Furth; Lothar Hennighausen
- Web page: https://patentgrep.com/patent/US6730663B2

## CPC

- C12N 15/89: using microinjection
- C12M 35/00: {Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion (machines for extracting juice from animal or plant tissue by electroplasmolysis A23N1/006, processes employing electric or wave energy B01J19/08; treatment of microorganisms or enzymes with electrical or wave energy C12N13/00; methods for cell fusion C12N15/02; introduction of foreign genetic material C12N15/87)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

The present invention provides a method of targeting transient gene expression and stable gene expression from the exogenous administration of a DNA sequence, which sequence is less than a complete genome, wherein said DNA sequence encodes RNA and protein, or RNA only, to differentiate tissue of living organisms wherein said DNA sequence through a jet injector technique, and said DNA sequence of less than a complete genome is expressed in a living organism. The present invention further provides a flexible multi-nozzle injector device with a wide surface area to allow molding of the injector nozzle to the surface contours of the tissue. Another aspect of the present invention provides an injection device having a long nozzle for injection of DNA deep into the host tissue. Also, in a further aspect the present invention provides an injector device modified to be used with and/or inject through an endoscopic device.

## Claims

### Claim 1

A method of targeting transient gene expression or stable gene expression in somatic cell tissue comprising: exogenously administering a plasmid expression vector to differentiated somatic cell tissue selected from the group consisting of skin, muscle, fat and mammary tissue of living organisms, using a jet injector, wherein said plasmid expression vector is expressed in a living organism.

### Claim 2 (depends on 1)

A method according to claim 1 further involving the steps of a member selected from the group consisting of (a) ablation of malignant cells by transient expression of the plasmid expression vector, (b) ablation of cells infected with specific viruses by transient expression of the plasmid expression vector, (c) immunization, (d) generation of chimeric organisms, (e) converting secretory cells of living organisms to produce a protein, (f) modifying the expression of endogenous gene, (g) providing a means for studying the effects of specific proteins in differentiated and undifferentiated tissue, (h) generating an animal model system for human diseases, and (i) the transient expression of a growth factor.

### Claim 3 (depends on 2)

A method according to claim 2 wherein the secretory cells of the living organism are mammary or bladder cells.

### Claim 4 (depends on 1)

A method according to claim 1 wherein said plasmid expression vector comprises DNA sequences selected form the group consisting of a DNA sequence claiming enhancer/promotor and other regulatory elements, a DNA sequence which can be transcribed into an RNA which RNA can be (a) translated into a protein, (b) includes a transcriptional termination signal, and (c) may include coding sequences for a signal peptide which allows a protein to be exported from the cell, a DNA sequence which targets a gene for incorporation into the genome, a DNA sequence which directly replicates in eukaryotic cells, and a plasmid sequence which allows DNA replication in prokaryotic cells.

### Claim 5 (depends on 4)

A method according to claim 4 wherein said DNA sequence is constructed using enhancer/promoter components, termination signals, and a signal peptide coding sequences from different genes.

### Claim 6 (depends on 2)

A method according to claim 2 wherein the enhancer/promoter sequence is a naturally occurring promoter/enhancer.

### Claim 7 (depends on 4)

A method according to claim 4 wherein the enhancer/promoter is composed of a generic TATA box and binding sites for the E2 transcription factor and said enhancer/promoter is coded by the papillomavirus genome, wherein said enhancer/promoter is expressed in cells capable of expressing the E2 protein from papillomavirus.

### Claim 8 (depends on 1)

The method of claim 1, wherein said differentiated tissue is selected from the group consisting of muscle, fat and mammary tissue.

### Claim 9 (depends on 1)

The method of claim 1, wherein said plasmid expression vector comprises a promoter-enhancer sequence selected from the group consisting of human cytomegalovirus immediate early gene 1 and whey acidic protein promoter sequence.

### Claim 10 (depends on 1)

The method of claim 1, wherein said plasmid expression vector comprises a hybrid gene selected from the group consisting of human cytomegalovirus immediate early gene 1 and chloramphenicol acetyl transferase gene; whey acidic protein promoter sequence and chloramphenicol acetyl transferase gene; and human cytomegalovirus immediate early gene 1 and β-galactosidase gene.

### Claim 11 (depends on 1)

The method of claim 1, wherein said plasmid expression vector is expressed in a living organism at about 1 to about 3 cm distant from the site of injection.

### Claim 12 (depends on 1)

The method of claim 1, wherein said plasmid expression vector comprises supercoiled DNA fragments of 1 microgram/microliter in 1 mM TRIS-0.1 mM EDTA and is administered in volumes between 100 microliters and 500 microliters per injection.

### Claim 13

A method for obtaining transient gene expression or stable gene expression in mammary tissue comprising: exogenously administering a plasmid expression vector, to mammary tissue of a living organisms, using a jet injector, wherein said plasmid expression vector is expressed in a living organism.

### Claim 14 (depends on 1)

A method according to claim 1, wherein said living organism is immunized by said plasmid expression vector which is expressed in said living organism.

### Claim 15

A method of immunization comprising the steps of jet injecting an effective amount of a plasmid expression vector, to transform differentiated somatic cell tissue of a living organisms selected from the group consisting of skin, muscle, fat and mammary tissue, wherein said plasmid expression vector is expressed in the living organism, and wherein DNA expressed from said plasmid expression vector immunizes said living organism.

### Claim 16 (depends on 2)

A method according to claim 2 wherein the enhancer/promoter sequence is the HCMVIE1 promoter/enhancer sequence.

### Claim 17 (depends on 2)

A method according to claim 2 wherein the enhancer/promoter sequence is an enhancer/promoter sequence constructed using specific DNA elements, which mediate binding by specific transcription factors to directly express only in specific cell types.
